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INTRODUCTION .
A previous report (Indian Council of Medical Research First Drug Resistance
Investigation, 1968) presented the results of a co-operative investigation on the pre-
valence of drug resistance in patients with pulmonary tuberculosis, presenting for the
first time with symptoms at chest clinics in India and giving no history of previous
antituberculosis chemotherapy. However, the information obtained from that investi-
gation is of rather limited value because, in most clinics, fairly large proportions of
patients reporting for the first time do so with a history of previous treatment. This is
because antituberculosis chemotherapy is offered not only by chest clinics, but also by
general hospitals and private practitioners. In these circumstances, information
on the prevalence of drug resistance among all patients, irrespective of the history of
previous antituberculosis chemotherapy, will be of great value, not only to the clinicians-
in-charge of the chest clinics but also to those responsible for formulating general policies
of treatment in the country. The second drug resistance investigation was undertaken
*This investigation was executed through a special sub-committee of the Indian Council of Medical
Research consisting of Drs. N.L. Bordia (Chairman), B.K. Sikand, P.K. Sen and M.D. Deshmukh,
Dr. P.R.J. Gangadharam, Senior Research Officer, Tuberculosis Chemotherapy Centre, Madras,
was seconded to look after the work of the Central Laboratory as well as to co-ordinate the work
of all the participating centres.
The following doctors participated from the various Centres : Dr. J.L. Bhatia (Amritsar),
Dr. R. Susaimary (Bangalore), Dr. M.D. Deshmukh (Bombay), Dr. N.N. Sen (Calcutta), Dr.
B.K. Sikand (Delhi), Dr. D. Umapathy Rao (Hyderabad), Dr. M.A. Hamid (Madras), Dr. P.A.
Deshmukh (Nagpur) and Dr. J.P. Karan (Patna).
The Central Laboratory was situated in the premises of the Tuberculosis Chemotherapy Centre,
Madras, and was afforded all the necessary facilities by the Director of the Centre (Dr. N.K.
Menon) and the Head of the Laboratory (Dr. S.P. Tripathy).
The analyses were undertaken and the report prepared by Dr. P.R.J. Gangadharam, assisted by
Miss V. Devaki (Research Assistant), and Mr. K. Mohan and Mr. A.S.L. Narayana (Statistical
Assistants). The report should be referred to as the Indian Council of Medical Research Second
Drug Resistance Investigation. Reprints can be obtained from the Director, Tuberculosis
Chemotherapy Centre, Chetput, Madras-31.
1
2 Drug Resistance in Patients with Pulmonary Tuberculosis.
by the Indian Council of Medical Research to obtain this information, and the findings
are presented below.
PLAN AND CONDUCT  OF THE INVESTIGATION .
Participating Centres.– The same 9 Centres which participated in the first investi-
gation participated in the present investigation. These Centres were situated at :
1. Amritsar (R.B. Sir Gujjarmal Kesardevi Tuberculosis Sanatorium),
2. Bangalore (Lady Willingdon Tuberculosis Demonstration and Training
Centre),
3. Bombay (Tuberculosis Clinic, J. J. Group of Hospitals),
4. Calcutta (K. S. Ray Tuberculosis Hospital),
5. Delhi (New Delhi Tuberculosis Centre),
6. Hyderabad (Institute of Diseases of Chest and Tuberculosis),
7. Madras (Government Tuberculosis Demonstration and Training Centre),
8. Nagpur (Tuberculosis Control and Training Centre), and
9. Patna (Tuberculosis Demonstration and Training Centre).
Criteria for eligibility of patients.– A patient was eligible for admission to the
investigation if he/she
(a) was aged 12 years or more,
(b) had resided in the area served by the clinic the previous year and was expected
to do so for another year,
(c) was attending the clinic for the first time and because of chest symptoms
(patients detected by mass miniature radiography were not eligible), and
(d) had radiographic evidence suggestive of tuberculosis (however, patients
with evidence of only minimal disease, calcification, pleural thickening,
hilar gland enlargement or fibrotic foci were not eligible).
Procedures followed by the participating Centres.– At each of the 9 Centres, a
specimen of sputum was collected (in a sterile universal container) from about 175
to 250 patients, under the direct supervision of the clinic staff, and des-
patched by air to the Central Laboratory at Madras ; if there was any delay in
despatching, the specimen was stored in an ice-box or a refrigerator, whenever this
was practicable.
In order that the Central Laboratory may not be overloaded with specimens,
each participating Centre was asked to restrict the number of specimens to 25 per
week. It was emphasized that these specimens were to be collected from the first 25
eligible patients who attended the clinic in that week.
At the time of the first attendance at the Centre, each patient was specifically
questioned as to whether he had received any antituberculosis drugs previously ; this
was done by the physician-in-charge and also, whenever possible, by other members
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of the staff. About 3 to 4 weeks later, a second interrogation was undertaken, with no
knowledge of the sensitivity test results.
Investigations undertaken by the Central Laboratory .-The following investigations
were undertaken :
(1) Direct smear examination using fluorescence microscopy (Holst, Mitchison
and Radhakrishna, 1959), positive results being graded as 3-plus (heavy), 2-plus
(moderate) or l-plus (scanty).
(2) Culture examination for tubercle bacilli, employing the technique described
by the Tuberculosis Chemotherapy Centre, Madras (1959). Growth typical of
Mycobacterium tuberculosis was recorded as 3-plus (confluent), 2-plus (innumerable
discrete colonies), l-plus (100-20 colonies) or the actual number of colonies, if less
than 20.
(3) Tests for sensitivity to isoniazid, streptomycin, PAS and thioacetazone*,
using the procedures described earlier (Indian Council of Medical Research First Drug
Resistance Investigation, loc. cit.), but with the concentrations of drugs set out below :
Drug concentration (µg.ml.)
Drug Test strain H37Rv
Isoniazid 0.2, 1, 5, 50 0.025, 0.05, 0.1, 0.2, 1
Streptomycin 4, 8, 16, 32, 64 1, 2, 4, 8
Sodium PAS dihydrate 0.5, 1, 2, 4, 8, 16 0.125, 0.25, 0.5, 1, 2
Thioacetazone 0.25, 0.5, 1, 2, 4, 8 0.25, 0.5, 1, 2, 4, 8
For isoniazid, streptomycin and thioacetazone, an approximately 4 mg./ml.
suspension of the culture was employed, while a 1 : 10 dilution was employed in the
case of PAS for reasons given by Selkon et al. (1960). A standard (approximately
3 mm.) loopful of the appropriate suspension was inoculated on to the Lowenstein-
Jensen slopes containing the drug concentrations set out above, as well as on to a drug-
free slope as control. The standard sensitive strain of Mycobacterium tuberculosis,
H37Rv, was also set up with each batch of tests. The results of all the tests were read
at the end of 4 weeks of incubation at 37°C. The results of isoniazid and thioacetazone
sensitivity tests were expressed as MICs–that is, the minimum concentrations of the
drugs inhibiting growth (defined as 20 colonies or more), while those of streptomycin
and PAS were expressed as resistance ratios-that is, the MICs of the test strains divided
by the corresponding MICs of H37Rv. If the MIC of isoniazid was 1 µg./ml. or the
resistance ratio for streptomycin or PAS was 4, the test was repeated.
Definitions of drug resistance.– The definitions of resistance employed were the
same as in the first drug resistance investigation, namely :
Isoniazid.– MIC of 5 or more, or 1 followed by 1 or more in the retest.
* Thioacetazone is the recommended international non-proprietary name (see World Health Org-
anization, 1962) for 4’-formylacetanilide thiosemicarbazone (thioacetazone, TB1-698).
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Streptomycin.– Resistance ratio of 8 or more, or 4 followed by 4 or more in the
retest.
PAS and thioacetazone.– As in the first drug resistance investigation and for the
same reasons, no formal definitions of resistance have been employed, the findings
being presented in the form of distributions.
(4) A series of identification tests for Mycobacterium tuberculosis, namely :
(a) niacin production-test as described by Medveczky (1960),
(b) qualitative test for catalase activity as described by Selkon and Mitchison
(1959),
(c) growth on Lowenstein-Jensen medium after incubation at 25°C. for 4 weeks,
and (d) pigmentation and morphology of growth after incubation at 37°C. for 4 weeks,
in the dark and in the light.
Intake of specimens.– The intake of specimens commenced in June 1965 and
concluded in April 1967, the period of intake for the individual Centres varying from
2 to 15 months. In all, 1890 specimens were obtained from the same number of patients
and despatched to the Central Laboratory from the 9 Centres. Of these, 28 (1.5 per
cent) have not been considered further in this report–1 because the specimen was
obtained from a patient who had attended the clinic earlier, 7 because they were from
patients who were less than 12 years of age, and 20 because the bottles had broken or
the sputum had leaked out during transit. The remaining 1,862 specimens are con-
sidered in the analyses.
RESULTS.
Sex and age.– Of the 1862 patients, 1177 (63 per cent) were males, the proportions
in the individual Centres ranging from 52 per cent in Amritsar to 74 per cent in Delhi.
The age distributions for the males and the females are presented in Table I, separately
and jointly for the 9 Centres.
Smear and culture results.– The results of direct smear and culture examination
of the sputum specimens are set out in Table II. In all, 67 per cent of the specimens
yielded a positive smear, the proportions in the individual centres varying from 37 per
cent in Calcutta to 85 per cent in Amritsar. The proportions of specimens which
yielded a positive culture ranged from 35 per cent in Calcutta to 84 per cent in Hyderabad,
the mean for the 9 Centres being 66 per cent.
There were 154 (8 per cent) specimens which yielded a smear-positive culture-
negative result, the proportions in individual centres ranging from 1 per cent
in Hyderabad to 23 per cent in Patna.
Contamination of the culture occurred in 144 (8 per cent) of the specimens, the
proportions ranging from 2 per cent in Madras to 13 per cent in Bombay. It occurred
in 9 per cent of 612 smear-negative specimens as compared with 7 per cent of 1,249
smear-positive specimens, fairly similar findings.
Centre.
Amritsar
Bangalore
Bombay
Calcutta
Delhi
Hyderabad
Madras
Nagpur
Patna
TABLE  I.
Distribution of patients according to sex and age.
Total.
103
117
179
1.59
147
115
137
127
93
MALES : FEMALES :
Percentage of patients : Percentage of patients :
Less than
25 years. Total.
18 34 20 27 95 32 35 15 18
32 30 16 21 82 35 40 16 9
35 25 20 20 67 34 34 24 7
23 21 28 28 89 33 35 16 17
20 34 19 27 52 38 37 15 10
17 32 23 29 82 20 55 16 10
18 29 23 31 63 30 43 14 13
27 32 16 25 73 36 38 19 7
27 25 24 24 82 56 26 10 9
All Centres 1177 24 29 21 25 685 35 38 16 11
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TABLE II.
Results of direct smear and culture examination of sputum specimens.
Centre.
Total
number of
specimens.
Amritsar
Bangalore
Bombay
Nagpur
Patna
197*
199
200
175
PERCENTAGE OF SPECIMENS WITH A :
Positive
smear.
All Centres 1861 67 66 8 8
*Excluding one specimen with no smear result.
Sensitivity test results.– Of the total of 1,862 specimens, 1,220 yielded a positive
culture, but 14 of these were found to contain atypical mycobacteria. Of the remaining
1,206 cultures, all of which were identified as Mycobacterium tuberculosis, 98.1 per cent
had a sensitivity test result for isoniazid, 98.1 per cent for streptomycin, 97.5 per cent
for PAS and 97.3 per cent for thioacetazone.
Isoniazid and streptomycin.– Table III presents the findings of isoniazid and stre-
ptomycin sensitivity tests for the 9 Centres. Considering all the Centres together,
the prevalence was 9.1 per cent for isoniazid alone and 7.0 per cent for streptomycin
TABLE III.
Findings of isoniazid and streptomycin sensitivity tests.
Centre.
Amritsar
Calcutta
Delhi
Hyderabad
Madras
Nagpur
Patna
Number of
cultures with
  H or S sensitivity
test results.
148
156
167
81
132
134 10
81 9
PERCENTAGE OF CULTURES RESISTANT TO :
2
15
All Centres 1183 9.1 7.0 15.8 25.0 22.9 32.0
H = isoniazid ; S = streptomycin.
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alone, the prevalence in individual Centres ranging from 4 per cent in Bombay to 14
per cent in Delhi for isoniazid alone, and from 4 per cent in Hyderabad to 15 per cent
in Patna for streptomycin alone. Resistance to both isoniazid and streptomycin
was observed in 15.8 per cent of the cultures ; excluding Calcutta which had a very high
proportion of 58 per cent, the range was 5 per cent (in Bangalore) to 25 per cent (in
Bombay).
The total resistance to isoniazid was 25.0 per cent and the total resistance
to streptomycin was 22.9 per cent. Considering the individual Centres, the prevalence
of total isoniazid resistance ranged from 15 per cent in Patna to 69 per cent in Calcutta,
while the prevalence of total resistance to streptomycin ranged from 12 per cent in
Bangalore to 63 per cent in Calcutta.
Finally, 32.0 per cent of the patients had resistance to at least one drug ; the pre-
valence in individual Centres varied considerably. In Table IV, the 9 Centres are ar-
ranged in the ascending order of this proportion and, in the next column, the proportion
of patients with a history of previous chemotherapy (of 10 days or more) is presented.
It can be seen that, in general, Centres with a high prevalence had a high proportion
of previously treated patients. Indeed, regression analysis of the data showed that over
90 per cent of the variation between the Centres in the proportion resistant could be
accounted for by differences in the proportion of previously treated patients.
TABLE IV.
Prevalence of resistance in the nine centres related to the percentage of patients
with a history of previous chemotherapy.
PERCENTAGE 0F PATIENTS WITH :
Centre. Resistance to 10 or more days
H or S of previous
or both. chemotherapy.
Bangalore
Hyderabad
Patna
Delhi
Calcutta
All Centres
Prevalence of resistance related to duration of previous chemotherapy.– There  was
very clear evidence that longer durations of previous chemotherapy were associated
with a higher prevalence of resistance (Table V). Thus, of 851 patients who had
received no chemotherapy previously (apart from 2 who had received 4 days of chemo-
therapy), 22 per cent had resistance to streptomycin or isoniazid or to both drugs,
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the corresponding proportions being 26, 33, 42, 52, 67, and 76 per cent in patients who
had received chemotherapy from 10 days to a month, 1-2 months, 2-3 months, 3-6
months, 6-12 months and 12 months or more, respectively. The trend in these
percentages is highly significant (P < 0.00001).
TABLE V.
Prevalence of resistance related to duration of previous chemotherapy.
Duration of Number of
chemotherapy. patients.
RESISTANCE TO H OR S OR BOTH:
Number. Per cent.
Nil*
10 days–
1 month–
2 months–
3 months–
6 months–
12 months or more
All patients 1183 379 32.0
* Including 2 patients who had 4 days of previous chemotherapy ; neither of
these had resistance. to either drug.
Prevalence of resistance related to sex and age of the patients.– The prevalence
of resistance was not associated with either the sex or the age of the patients. Thus,
31.7 per cent of 754 males had resistance to streptomycin or isoniazid or both drugs,
as compared with 32.4 per cent of 429 females. The prevalence was 31, 35, 30 and
31 per cent in patients aged less than 25 years, 25-34 years, 35-44 years and 45 years
or more, respectively. Similar conclusions were reached on relating separately
the prevalence of streptomycin resistance and that of isoniazid resistance to the sex
and age of the patients.
PAS.– The results of PAS sensitivity tests are set out in the form of distributions
in Table VI. Considering all the 9 Centres, 9.7 per cent had a resistance ratio (RR)
of 8 or more, 7.1 per cent an RR of 4 and the remaining 83.2 per cent an RR of 2 or less.
The proportion with an RR of 8 or more was particularly high in Calcutta (36 per cent),
and ranged from 2 per cent to 11 per cent in the other Centres.
Thioacetazone.– The findings of thioacetazone sensitivity tests are set out in
Table VII in the form of distributions. Considering all the 9 Centres, 55.4 per cent
had an MIC of 1 µg./ml. or less, 20.0 per cent had an MIC of 2 µg./ml., and 24.6 per cent
had an MIC of 4 µg./ml. or more. In the individual Centres, the proportion with a low
MIC (1 µg./ml. or less) ranged from 38 per cent in Madras and to 71 per cent in
Patna.
Findings in patients with no history of previous chemotherapy.– Among the patients
in this investigation who had no history of previous chemotherapy, 15.5 per cent had
an isoniazid-resistant culture and 13.8 per cent a streptomycin-resistant culture ; the
corresponding proportions in an earlier investigation (Indian Council of Medical
Research First Drug “Resistance Investigation, loc. cit.), were similar, namely, 14.5
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TABLE  VI.
Findings of PAS sensitivity tests.
Centre. Number of
A RESISTANCE RATIO OF:
cultures tested.
2 or less. 4 8 or more.
All Centres 1175 83.2 7.1 9.7
TABLE  VII.
Findings of thioacetazone sensitivity tests.
Centre.
Number of
PERCENTAGE OF CULTURES WITH AN
cultures
MIC (µg./ml.) OF :
tested.
1 or less. 2 4 or more.
Amritsar
Bangalore
Bombay
Calcutta
Delhi
All Centres
and 11.8 per cent, respectively (Table VIII). The findings in the individual centres
are also fairly similar with the exception of Patna where the prevalence of isoniazid
resistance was 5 per cent of 57 in this investigation and 18 per cent of 130 in the earlier
investigation, a significant difference (P=0.04).
The findings in this investigation also confirm the existence of large differences
between the Centres in the susceptibility to thioacetazone of strains from untreated
patients (last two columns of Table VIII) ; in particular, strains from Madras patients
were less susceptible, the geometric mean of the MICs being 2.10 µg./ml. in the present
investigation and 2.38 µg./ml. in the earlier investigation.
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TABLE  VIII.
Findings in patients with no history of previous chemotherapy.
PERCENTAGE OF CULTURES   PERCENTAGEOF CULTURES GEOMETRIC MEAN OF MIC
Centre*.
Amritsar
Bangalore
Hyderabad
Nagpur
Patna
RESISTANT TO ISONIAZID.   RESISTANT TO STREPTOMYCIN.  OF THIOACETAZONE (µg./ml.)
Present Earlier Present Earlier Present Earlier
report. report†. report. report†. report. report†.
All Centres 155 14.5 13.8 11.8 1.49 1.21
*Excluding Calcutta since, in the present investigation, only 8 of the positive cultures were from
untreated patients.
† Indian Council of Medical Research First Drug Resistance Investigation (loc. cit.).
DISCUSSION .
This report gives information on the prevalence of drug resistance in tuberculous
patients reporting for the first time with symptoms at 9 chest clinics in India. The
investigation is based on all patients–that is, regardless of whether or not they had
received chemotherapy previously from any other source, and the findings therefore
give some indication of the problems involved in evolving suitable chemotherapeutic
regimens for routine use at chest clinics in the country.
Considering all the Centres, 25.0 per cent of the patients had resistance to isoniazid
and 22.9 per cent to streptomycin, including 15.8 per cent with resistance to both the
drugs. In other words, 32.0 per cent of the patients had resistance to one or both
of these very potent drugs, These findings are broadly similar to those reported from
Hong Kong (Hong Kong/British Medical Research Council Drug Resistance Survey,
1964), where 33 per cent of the patients had isoniazid resistance and 23 per cent had
streptomycin resistance.
In the present investigation, the prevalence of resistance was not. associated with
either the sex or the age of the patients. However, it was, as may be expected, closely
correlated with the duration of previous chemotherapy ; thus, the prevalence of resistance
(to either or both drugs) was 22 per cent in patients who had no history of previous
chemotherapy and 26, 33, 42, 52, 67 and 76 per cent in patients who had received
chemotherapy for 10 days to a month, 1-2 months, 2-3 months, 3-6 months, 6-12
months and 12 months or more, respectively.
Considering next the findings in individual Centres, the prevalence of resistance
(to one or both drugs) varied considerably, the proportion being 22 per cent in Nagpur,
23 per cent in both Madras and Bangalore, 27 per cent in Hyderabad, 30 per cent in
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Patna, 33 per cent in both Delhi and Amritsar, 39 per cent in Bombay and 74 per cent
in Calcutta. However, further analyses showed that over 90 per cent of the variation
between the Centres could be explained by differences between them in the propor-
tion of patients with a history of previous chemotherapy.
Among the patients with no history of previous chemotherapy, the prevalence of
isoniazid resistance was 155 per cent in the present investigation as compared with
14.5 per cent in an earlier investigation (Table VIII) ; the corresponding proportions
for streptomycin resistance were 13.8 per cent and 11.8 per cent respectively. The
similarity of these figures is gratifying, and enhances the confidence that can be placed
on the findings of the earlier investigation. Finally, the results of the present investi-
gation confirm that there are large differences between the Centres in the susceptibility
to thioacetazone of strains from untreated patients and, in particular, that strains
from Madras patients are less susceptible than those from the other Centres.
As in the earlier investigation, the co-operation obtained from the participating
Centres was of a high order, a finding which is encouraging for the conduct of future
bacteriological investigations in India on a cooperative basis.
SUMMARY.
1. A co-operative investigation was undertaken to estimate the prevalence of
drug resistance in tuberculous patients reporting for the first time, with or without a
history of previous chemotherapy, at 9 urban chest clinics in different parts of India.
2. At each Centre, one specimen of sputum was collected from each of about
175-250 patients and despatched by air to a Central Laboratory at Madras.
3. The prevalence of resistance, based on about 1,200 positive cultures from the
9 Centres, was 25.0 per cent to isoniazid and 22.9 per cent to streptomycin, including
15.8 per cent to both the drugs.
4. The prevalence was very high in Calcutta, namely, 69 per cent to isoniazid
and 63 per cent to streptomycin, but so also was the proportion of patients with a
history of previous chemotherapy, namely 90 per cent. At the other Centres, the pre-
valence of isoniazid resistance ranged from 15 per cent to 29 per cent, and streptomycin
resistance from 12 per cent to 35 per cent.
Besides the Officers-in-charge, several other staff members of the participating
Centres contributed to the success of this investigation. Competent technical assistance
was rendered by the technicians of the Central Laboratory. Mr. P.R. Somasundaram
gave valuable advice regarding the analyses of the material and the preparation of the
report.
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APPENDIX.
Towards the end of the investigation reported in the preceding pages, the Indian
Council of Medical Research decided to obtain similar information from 7 more Centres,
namely, (1) V.M. Hospital, Agartala (Dr. B.C. Arora succeeded by Dr. N. Debbarma),
(2) Tuberculosis Demonstration and Training Centre, Agra (Dr. M.L. Mehrotra),
(3) K.N. State Tuberculosis Demonstration and Training Centre, Ajmer (Dr. P.N.
Sharma), (4) District Tuberculosis Centre, Aurangabad (Dr. S.A. Jaleel), (5) Tuberculosis
Control Centre, Panaji (Dr. M.R. de Menezes Mesquita), (6) Tuberculosis Clinic,
Pondicherry (Dr. K.V. Ramanujam), and (7) District Tuberculosis Centre, Quilon
(Dr. P. Srinivasan).
In the event, however, the numbers of sputum specimens obtained from Pondicherry
and Quilon were too few, as was the number of positive cultures from Aurangabad.
Consequently, the findings of isoniazid and streptomycin sensitivity tests are presented
below, together with the proportions of patients with a history of previous chemotherapy,
for the remaining 4 Centres only–namely, Agartala, Agra, Ajmer and Panaji.
Centre.
Agartala
Agra
Ajmer
Panaji
Number of
patients with
sensitivity
test results.
143
120
PERCENTAGE OF PATIENTS WITH RESISTANCE TO :
Isoniazid.
